Androgen-Sensitive Microsomal Signaling Networks Coupled to the Proliferation and Differentiation of Human Prostate Cancer Cells

Genes and Cancer

Volumn 2, Issue 10, 2011, Pages 956-978

  Martinez, Harryl D ^a,b,c   Hsiao, Jordy J ^c   Jasavala, Rohini J ^a,b   Hinkson, Izumi V ^a,b   Eng, Jimmy K ^d   Wright, Michael E ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

androgen; prostate cancer; protein networks; quantitative proteomics

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; I KAPPA B KINASE; I KAPPA B KINASE COMPLEX ASSOCIATED PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; JANUS KINASE 2; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S6 KINASE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; ENZYME ACTIVATION; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN CELL; MALE; MICROSOME; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 84868660527     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912436422     Document Type: Article

References (102)

1. Wilson JD,Griffin JE,George FW,Leshin M.The endocrine control of male phenotypic development.Aust J Biol Sci. 1983;36 (2): 101-28.
2. Gelmann EP.Molecular biology of the androgen receptor.J Clin Oncol. 2002;20 (13): 3001-15.
3. Keller ET,Rowley DR,Tomlins SA, et al.Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy.Cancer Res. 2007;67 (20): 9613-5.
4. Tomlins SA,Rhodes DR,Perner S, et al.Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.Science. 2005;310 (5748): 644-8.
5. Mehra R,Tomlins SA,Shen R, et al.Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.Mod Pathol. 2007;20 (5): 538-44.
6. Mehra R,Han B,Tomlins SA, et al.Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.Cancer Res. 2007;67 (17): 7991-5.
7. Helgeson BE,Tomlins SA,Shah N, et al.Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.Cancer Res. 2008;68 (1): 73-80.
8. Tomlins SA, et al.Role of the TMPRSS2-ERG gene fusion in prostate cancer.Neoplasia. 2008;10 (2): 177-88.
9. Yu J,Yu J,Mani RS, et al.An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.Cancer Cell. 2010;17 (5): 443-54.
10. Cai H,Babic I,Wei X,Huang J,Witte ON.Invasive prostate carcinoma driven by c-Src and androgen receptor synergy.Cancer Res. 2011;71 (3): 862-72.
11. DePrimo SE,Diehn M,Nelson JB, et al.Transcriptional programs activated by exposure of human prostate cancer cells to androgen.Genome Biol. 2002;3 (7):.
12. Ngan S,Stronach EA,Photiou A,Waxman J,Ali S,Buluwela L.Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells.Oncogene. 2009;28 (19): 2051-63.
13. Amler LC,Agus DB,LeDuc C, et al.Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.Cancer Res. 2000;60 (21): 6134-41.
14. Bubendorf L,Kolmer M,Kononen J, et al.Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.J Natl Cancer Inst. 1999;91 (20): 1758-64.
15. Chen CD,Welsbie DS,Tran C, et al.Molecular determinants of resistance to antiandrogen therapy.Nat Med. 2004;10 (1): 33-9.
16. Dhanasekaran SM,Dash A,Yu J, et al.Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty.FASEB J. 2005;19 (2): 243-5.
17. Nelson PS,Clegg N,Arnold H, et al.The program of androgen-responsive genes in neoplastic prostate epithelium.Proc Natl Acad Sci U S A. 2002;99 (18): 11890-5.
18. Shao C,Wang Y,Yue HH, et al.Biphasic effect of androgens on prostate cancer cells and its correlation with androgen receptor coactivator dopa decarboxylase.J Androl. 2007;28 (6): 804-12.
19. Waltering KK,Helenius MA,Sahu B, et al.Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.Cancer Res. 2009;69 (20): 8141-9.
20. Lin B,Wang J,Hong X, et al.Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor.PLoS One. 2009;4 (8): e6589.
21. Lamont KR,Tindall DJAdvances in cancer research. George FVWGeorge K, ed. Waltham, MA: Academic Press; 2010:137-62.
22. Schwanhausser B,Busse D,Li N, et al.Global quantification of mammalian gene expression control.Nature. 2011;473 (7347): 337-42.
23. Martin DB,Gifford DR,Wright ME, et al.Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium.Cancer Res. 2004;64 (1): 347-55.
24. Vellaichamy A,Dezso Z,JeBailey L, et al."Topological significance" analysis of gene expression and proteomic profiles from prostate cancer cells reveals key mechanisms of androgen response.PLoS One. 2010;5 (6): e10936.
25. Vellaichamy A,Sreekumar A,Strahler JR, et al.Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases.PLoS One. 2009;4 (9): e7075.
26. Youm YH,Kim S,Bahk YY,Yoo TK.Proteomic analysis of androgen-independent growth in low and high passage human LNCaP prostatic adenocarcinoma cells.BMB Rep. 2008;41 (10): 722-7.
27. Wright ME,Eng J,Sherman J, et al.Identification of androgen-coregulated protein networks from the microsomes of human prostate cancer cells.Genome Biol. 2003;5 (1): R4.
28. Pang B,Zhang H,Wang J, et al.Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.Prostate. 2009;69 (11): 1176-87.
29. Rowland JG,Robson JL,Simon WJ,Leung HY,Slabas AR.Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells.Proteomics. 2007;7 (1): 47-63.
30. Meehan KL,Sadar MD.Quantitative profiling of LNCaP prostate cancer cells using isotope-coded affinity tags and mass spectrometry.Proteomics. 2004;4 (4): 1116-34.
31. Fujiki Y,Hubbard AL,Fowler S,Lazarow PB.Isolation of intracellular membranes by means of sodium carbonate treatment: application to endoplasmic reticulum.J Cell Biol. 1982;93 (1): 97-102.
32. Wang G,Wang J,Sadar MD.Crosstalk between the androgen receptor and β-catenin in castrate-resistant prostate cancer.Cancer Res. 2008;68 (23): 9918-27.
33. Liu XH,Kirschenbaum A,Yao S,Liu G,Aaronson SA,Levine AC.Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells.Cancer Res. 2007;67 (12): 5747-53.
34. Yang F,Li X,Sharma M, et al.Linking β-catenin to androgen-signaling pathway.J Biol Chem. 2002;277 (13): 11336-44.
35. Mulholland DJ,Cheng H,Reid K,Rennie PS,Nelson CC.The androgen receptor can promote β-catenin nuclear translocation independently of adenomatous polyposis coli.J Biol Chem. 2002;277 (20): 17933-43.
36. Chesire DR,Isaacs WB.Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor.Oncogene. 2002;21 (55): 8453-69.
37. Chesire DR,Ewing CM,Gage WR,Isaacs WB.In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis.Oncogene. 2002;21 (17): 2679-94.
38. Yu X,Wang Y,DeGraff DJ,Wills ML,Matusik RJ.Wnt/[beta]-catenin activation promotes prostate tumor progression in a mouse model.Oncogene. 2011;30 (16): 1868-79.
39. Guo Z,Dai B,Jiang T, et al.Regulation of androgen receptor activity by tyrosine phosphorylation.Cancer Cell. 2006;10 (4): 309-19.
40. Cai H,Smith DA,Memarzadeh S,Lowell CA,Cooper JA,Witte ON.Differential transformation capacity of Src family kinases during the initiation of prostate cancer.Proc Natl Acad Sci U S A. 2011;108 (16): 6579-84.
41. Desai SJ,Ma AH,Tepper CG,Chen HW,Kung HJ.Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications.Cancer Res. 2006;66 (21): 10449-59.
42. Lee LF,Guan J,Qiu Y,Kung HJ.Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.Mol Cell Biol. 2001;21 (24): 8385-97.
43. Lee LF,Louie MC,Desai SJ, et al.Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.Oncogene. 2004;23 (12): 2197-205.
44. Lamont KR,Tindall DJ.Minireview: alternative activation pathways for the androgen receptor in prostate cancer.Mol Endocrinol. 2011;25 (6): 897-907.
45. Ordóñez-Morán P,Muñoz A.Nuclear receptors: genomic and non-genomic effects converge.Cell Cycle. 2009;8 (11): 1675-80.
46. Hu T,Li C.Convergence between Wnt-beta-catenin and EGFR signaling in cancer.Mol Cancer. 2010;9 (1): 236.
47. Fox EM,Andrade J,Shupnik MA.Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways.Steroids. 2009;74 (7): 622-7.
48. Shupnik MA.Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation.Oncogene. 2004;23 (48): 7979-89.
49. Burchardt T,Burchardt M,Chen MW, et al.Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.J Urol. 1999;162 (5): 1800-5.
50. Wright ME,Tsai MJ,Aebersold R.Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells.Mol Endocrinol. 2003;17 (9): 1726-37.
51. Sarker D,Reid AH,Yap TA,de Bono JS.Targeting the PI3K/AKT pathway for the treatment of prostate cancer.Clin Cancer Res. 2009;15 (15): 4799-805.
52. Xu Y,Chen SY,Ross KN,Balk SP.Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.Cancer Res. 2006;66 (15): 7783-92.
53. Montgomery BT,Young CY,Bilhartz DL, et al.Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP.Prostate. 1992;21 (1): 63-73.
54. Young CY,Montgomery BT,Andrews PE,Qui SD,Bilhartz DL,Tindall DJ.Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP.Cancer Res. 1991;51 (14): 3748-52.
55. Zegarra-Moro OL,Schmidt LJ,Huang H,Tindall DJ.Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells.Cancer Res. 2002;62 (4): 1008-13.
56. Sedelaar JP,Isaacs JT.Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone.Prostate. 2009;69 (16): 1724-9.
57. Ferrari S,Bandi HR,Hofsteenge J,Bussian BM,Thomas G.Mitogen-activated 70K S6 kinase: identification of in vitro 40 S ribosomal S6 phosphorylation sites.J Biol Chem. 1991;266 (33): 22770-5.
58. Flotow H,Thomas G.Substrate recognition determinants of the mitogen-activated 70K S6 kinase from rat liver.J Biol Chem. 1992;267 (5): 3074-8.
59. Pullen N,Thomas G.The modular phosphorylation and activation of p70s6k.FEBS Lett. 1997;410 (1): 78-82.
60. Fadden P,Haystead TA,Lawrence JC.Identification of phosphorylation sites in the translational regulator, PHAS-I, that are controlled by insulin and rapamycin in rat adipocytes.J Biol Chem. 1997;272 (15): 10240-7.
61. Gingras AC,Gygi SP,Raught B, et al.Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism.Genes Dev. 1999;13 (11): 1422-37.
62. Zhang J,Gao N,Kasper S,Reid K,Nelson C,Matusik RJ.An androgen-dependent upstream enhancer is essential for high levels of probasin gene expression.Endocrinology. 2004;145 (1): 134-48.
63. Liu X,Choi RY,Jawad SM,Arnold JT.Androgen-induced PSA expression requires not only activation of AR but also endogenous IGF-I or IGF-I/PI3K/Akt signaling in human prostate cancer epithelial cells.Prostate. 2011;71 (7): 766-77.
64. Abrahamsson PA.Neuroendocrine differentiation in prostatic carcinoma.Prostate. 1999;39 (2): 135-48.
65. Langeler EG,van Uffelen CJ,Blankenstein MA,van Steenbrugge GJ,Mulder E.Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP.Prostate. 1993;23 (3): 213-23.
66. van Steenbrugge GJ,van Uffelen CJ,Bolt J,Schröder FH.The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity.J Steroid Biochem Mol Biol. 1991;40 (1-3): 207-14.
67. Berger R,Febbo PG,Majumder PK, et al.Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells.Cancer Res. 2004;64 (24): 8867-75.
68. de Launoit Y,Veilleux R,Dufour M,Simard J,Labrie F.Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells.Cancer Res. 1991;51 (19): 5165-70.
69. Kraus S,Gioeli D,Vomastek T,Gordon V,Weber MJ.Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor.Cancer Res. 2006;66 (22): 11047-54.
70. Sun M,Yang L,Feldman RI, et al.Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src.J Biol Chem. 2003;278 (44): 42992-3000.
71. Oda A,Druker BJ,Ariyoshi H,Smith M,Salzman EW.pp60src is an endogenous substrate for calpain in human blood platelets.J Biol Chem. 1993;268 (17): 12603-8.
72. Harris KF,Shoji I,Cooper EM,Kumar S,Oda H,Howley PM.Ubiquitin-mediated degradation of active Src tyrosine kinase.Proc Natl Acad Sci U S A. 1999;96 (24): 13738-43.
73. Hakak Y,Martin GS.Ubiquitin-dependent degradation of active Src.Curr Biol. 1999;9 (18): 1039-42.
74. Tomlins SA,Laxman B,Dhanasekaran SM, et al.Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.Nature. 2007;448 (7153): 595-9.
75. Klezovitch O,Risk M,Coleman I, et al.A causal role for ERG in neoplastic transformation of prostate epithelium.Proc Natl Acad Sci U S A. 2008;105 (6): 2105-10.
76. Zong Y,Xin L,Goldstein AS,Lawson DA,Teitell MA,Witte ON.ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.Proc Natl Acad Sci U S A. 2009;106 (30): 12465-70.
77. Yan Y,Sheppard PC,Kasper S, et al.Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice.Prostate. 1997;32 (2): 129-39.
78. Johnson MA,Hernandez I,Wei Y,Greenberg N.Isolation and characterization of mouse probasin: an androgen-regulated protein specifically expressed in the differentiated prostate.Prostate. 2000;43 (4): 255-62.
79. Holmberg C,Katz S,Lerdrup M, et al.A novel specific role for IκB kinase complex-associated protein in cytosolic stress signaling.J Biol Chem. 2002;277 (35): 31918-28.
80. Rahl PB,Chen CZ,Collins RN.Elp1p, the yeast homolog of the FD disease syndrome protein, negatively regulates exocytosis independently of transcriptional elongation.Mol Cell. 2005;17 (6): 841-53.
81. Cuajungco MP,Leyne M,Mull J, et al.Tissue-specific reduction in splicing efficiency of IKBKAP due to the major mutation associated with familial dysautonomia.Am J Hum Genet. 2003;72 (3): 749-58.
82. Cohen L,Henzel WJ,Baeuerle PA.IKAP is a scaffold protein of the I[kappa]B kinase complex.Nature. 1998;395 (6699): 292-6.
83. Close P,Hawkes N,Cornez I, et al.Transcription impairment and cell migration defects in elongator-depleted cells: implication for familial dysautonomia.Mol Cell. 2006;22 (4): 521-31.
84. Wittschieben BO,Otero G,de Bizemont T, et al.A novel histone acetyltransferase is an integral subunit of elongating RNA polymerase II holoenzyme.Mol Cell. 1999;4 (1): 123-8.
85. Otero G,Fellows J,Li Y, et al.Elongator, a multisubunit component of a novel RNA polymerase II holoenzyme for transcriptional elongation.Mol Cell. 1999;3 (1): 109-18.
86. Creppe C,Malinouskaya L,Volvert ML, et al.Elongator controls the migration and differentiation of cortical neurons through acetylation of alpha-tubulin.Cell. 2009;136 (3): 551-64.
87. Ai J,Wang Y,Dar JA, et al.HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.Mol Endocrinol. 2009;23 (12): 1963-72.
88. Zhu ML,Horbinski CM,Garzotto M,Qian DZ,Beer TM,Kyprianou N.Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.Cancer Res. 2010;70 (20): 7992-8002.
89. Heinlein CA,Chang C.The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions.Mol Endocrinol. 2002;16 (10): 2181-7.
90. Johansen LD,Naumanen T,Knudsen A, et al.IKAP localizes to membrane ruffles with filamin A and regulates actin cytoskeleton organization and cell migration.J Cell Sci. 2008;121 (6): 854-64.
91. Wood ZA,Schröder E,Robin Harris J,Poole LB.Structure, mechanism and regulation of peroxiredoxins.Trends Biochem Sci. 2003;28 (1): 32-40.
92. Parmigiani RB,Xu WS,Venta-Perez G, et al.HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation.Proc Natl Acad Sci U S A. 2008;105 (28): 9633-8.
93. Park SY,Yu X,Ip C,Mohler JL,Bogner PN,Park YM.Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation.Cancer Res. 2007;67 (19): 9294-303.
94. Horoszewicz JS,Leong SS,Kawinski E, et al.LNCaP model of human prostatic carcinoma.Cancer Res. 1983;43 (4): 1809-18.
95. Yates JR, et al.Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database.Anal Chem. 1995;67 (8): 1426-36.
96. Gygi SP,Rist B,Gerber SA,Turecek F,Gelb MH,Aebersold R.Quantitative analysis of complex protein mixtures using isotope-coded affinity tags.Nat Biotechnol. 1999;17 (10): 994-9.
97. Han DK,Eng J,Zhou H,Aebersold R.Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry.Nat Biotechnol. 2001;19 (10): 946-51.
98. Keller A,Purvine S,Nesvizhskii AI,Stolyar S,Goodlett DR,Kolker E.Experimental protein mixture for validating tandem mass spectral analysis.Omics. 2002;6:207-12.
99. Nesvizhskii AI,Keller A,Kolker E,Aebersold R.A statistical model for identifying proteins by tandem mass spectrometry.Anal Chem. 2003;75 (17): 4646-58.
100. Shevchenko A,Tomas H,Havlis J,Olsen JV,Mann M.In-gel digestion for mass spectrometric characterization of proteins and proteomes.Nat Protoc. 2006;1 (6): 2856-60.
101. Freshney RICulture of animal cells: a manual of basic technique. 4th ed.New York: Wiley; 2000.New York: Wiley; 2000:.
102. Martinez HD,Jasavala RJ,Hinkson I, et al.RNA editing of androgen receptor gene transcripts in prostate cancer cells.J Biol Chem. 2008;283 (44): 29938-49.